PF-08046054 by Pfizer for Melanoma: Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Melanoma.

Lack of clean water, sanitation, and hygienic controls in Cambodia promotes emergence of drug-resistant E. coli

A new study suggests that Escherichia coli and other disease-causing microbes are passing easily between humans and animals in Cambodia, a country where clean water,

September 19, 2023

Risk Adjusted Net Present Value: What is the current valuation of Pfizer’s Idrebormilast

The revenue for Idrebormilast is expected to reach an annual total of $43 mn by 2040 globally based off GlobalData’s Revenue Model. The drug’s revenue

July 2, 2024

Federal court backs FDA’s approval of competitor to Jazz’s sleep drug

The US District Court for Washington, DC, on Wednesday ruled against Jazz Pharmaceuticals’ attempt to undo the FDA’s approval of a competing sleep drug from

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.